Skip to main content

Table 2 Bacterial counts and pH (m ± SEM, log cfu/g) in 40 healthy volunteers assigned to a 7-d consumption of short-chain fructo-oligosaccharides (scFOS) at a dose from 2.5 to 10 g/d or a placebo

From: The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans

scFOS dose (g/d) Lactobacillus Bacteroides Enterobacteria pH
  d8* d15* P** d8* d15* P** d8* d15* P** d8* d15* P**
0 (placebo) 5.21 ± 0.36 5.18 ± 0.41 *** 8.76 ± 0.45 8.53 ± 0.32 *** 6.93 ± 0.29 7.07 ± 0.37 *** 6.94 ± 0.13 6.91 ± 0.11 ***
2.5 4.66 ± 0.48 5.14 ± 0.60 NS 8.93 ± 0.28 9.08 ± 0.17 NS 6.93 ± 0.26 7.28 ± 0.33 NS 6.68 ± 0.18 6.75 ± 0.14 NS
5.0 5.34 ± 0.66 5.99 ± 0.67 NS 8.87 ± 0.18 9.09 ± 0.28 NS 7.34 ± 0.33 7.81 ± 0.32 NS 6.48 ± 0.15 6.52 ± 0.11 NS
7.5 5.37 ± 0.40 5.97 ± 0.39 NS 8.74 ± 0.25 8.61 ± 0.29 NS 6.30 ± 0.29 6. 78 ± 0.26 NS 6.66 ± 0.13 6. 78 ± 0.13 NS
10 5.40 ± 0.41 5.73 ± 0.83 NS 8.51 ± 0.41 9. 39 ± 0.26 NS 6.28 ± 0.40 6.58 ± 0.32 NS 7.05 ± 0.21 7.20 ± 0.25 NS
  1. *days 1–8 was a run-in period during which no treatment occurred, but subjects excluded from their diet fermented dairy products containing viable bifidobacteria and limited consumption of food products containing high level of non-digestible oligosaccharides.
  2. ** Statistical analyses were performed versus placebo, on the difference d15-d8, using an unpaired t-test
  3. *** As the difference days 15-8 with placebo was the reference, p-values are not reported.